Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
International Journal of Radiation Oncology, Biology, Physics|October 9, 2007
Are increased tumor aneuploidy and heightened cell proliferation along with heterogeneity associated with patient outcome for carcinomas of the uterine cervix? A combined analysis of subjects treated in RTOG 9001 and a single-institution trialAaron H Wolfson, Kathryn Winter, William Crook, et al.Frontiers in Oncology|August 28, 2014
HPV in HIV-Infected Women: Implications for Primary PreventionNathalie Dauphin McKenzie, Erin N Kobetz, Parvin Ganjei-Azar, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinomaSusan K Lutgendorf, Donald M Lamkin, Nicholas B Jennings, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2014
Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group studyPaul A DiSilvestro, Shamshad Ali, Peter S Craighead, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patientsSusan K Lutgendorf, Aliza Z Weinrib, Frank Penedo, et al.NAR Genomics and Bioinformatics|June 30, 2025
Novel treatment-specific causal biomarkers for colorectal cancer by omics integrationAkram Yazdani, Azam Yazdani, Raul Mendez-Giraldez, et al.Cancer|May 1, 2021
Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancerArlene E Garcia-Soto, Nathalie D McKenzie, Margaret E Whicker, et al.Gynecologic Oncology|October 27, 2019
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG studyRoisin E O'Cearbhaill, Wei Deng, Lee-May Chen, et al.Brain, Behavior, and Immunity|August 14, 2012
Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disabilityAndrew Schrepf, Lauren Clevenger, Desire Christensen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
Social influences on clinical outcomes of patients with ovarian cancerSusan K Lutgendorf, Koen De Geest, David Bender, et al.Pageof 4